REPORT ID 2993

United States Bioengineered Protein Drugs Market Report 2017

Publish Date
12-Dec-17
Pages
112
Format
Electronic (PDF)

In this report, the United States Bioengineered Protein Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report splits the United States market into seven regions:
    The West
    Southwest
    The Middle Atlantic
    New England
    The South
    The Midwest
with sales (volume), revenue (value), market share and growth rate of Bioengineered Protein Drugs in these regions, from 2012 to 2022 (forecast).

United States Bioengineered Protein Drugs market competition by top manufacturers/players, with Bioengineered Protein Drugs sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
    Abbott Laboratories
    F. Hoffmann-La Roche Ltd
    Amgen, Inc.
    Bayer AG
    Merck & Co., Inc.
    Dr. Reddy?s Laboratories Ltd.
    Biocon Ltd.
    Eli Lilly and Company
    Sanofi
    GlaxoSmithKline plc
    Johnson & Johnson
    JanssenNovartis AG
    Panacea Biotec
    ProBioGen AG

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
    Therapeutic Proteins
    Monoclonal Antibodies
    Vaccines
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
    Diabetes and Hormonal Disorders
    Genetic and Fertility Disorders
    Cancers
    Organ Transplants
    Others

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

United States Bioengineered Protein Drugs Market Report 2017
1 Bioengineered Protein Drugs Overview
    1.1 Product Overview and Scope of Bioengineered Protein Drugs
    1.2 Classification of Bioengineered Protein Drugs by Product Category
        1.2.1 United States Bioengineered Protein Drugs Market Size (Sales Volume) Comparison by Type (2012-2022)
        1.2.2 United States Bioengineered Protein Drugs Market Size (Sales Volume) Market Share by Type (Product Category) in 2016
        1.2.3 Therapeutic Proteins
        1.2.4 Monoclonal Antibodies
        1.2.5 Vaccines
    1.3 United States Bioengineered Protein Drugs Market by Application/End Users
        1.3.1 United States Bioengineered Protein Drugs Market Size (Consumption) and Market Share Comparison by Application (2012-2022)
        1.3.2 Diabetes and Hormonal Disorders
        1.3.3 Genetic and Fertility Disorders
        1.3.4 Cancers
        1.3.5 Organ Transplants
        1.3.6 Others
    1.4 United States Bioengineered Protein Drugs Market by Region
        1.4.1 United States Bioengineered Protein Drugs Market Size (Value) Comparison by Region (2012-2022)
        1.4.2 The West Bioengineered Protein Drugs Status and Prospect (2012-2022)
        1.4.3 Southwest Bioengineered Protein Drugs Status and Prospect (2012-2022)
        1.4.4 The Middle Atlantic Bioengineered Protein Drugs Status and Prospect (2012-2022)
        1.4.5 New England Bioengineered Protein Drugs Status and Prospect (2012-2022)
        1.4.6 The South Bioengineered Protein Drugs Status and Prospect (2012-2022)
        1.4.7 The Midwest Bioengineered Protein Drugs Status and Prospect (2012-2022)
    1.5 United States Market Size (Value and Volume) of Bioengineered Protein Drugs (2012-2022)
        1.5.1 United States Bioengineered Protein Drugs Sales and Growth Rate (2012-2022)
        1.5.2 United States Bioengineered Protein Drugs Revenue and Growth Rate (2012-2022)

2 United States Bioengineered Protein Drugs Market Competition by Players/Suppliers
    2.1 United States Bioengineered Protein Drugs Sales and Market Share of Key Players/Suppliers (2012-2017)
    2.2 United States Bioengineered Protein Drugs Revenue and Share by Players/Suppliers (2012-2017)
    2.3 United States Bioengineered Protein Drugs Average Price by Players/Suppliers (2012-2017)
    2.4 United States Bioengineered Protein Drugs Market Competitive Situation and Trends
        2.4.1 United States Bioengineered Protein Drugs Market Concentration Rate
        2.4.2 United States Bioengineered Protein Drugs Market Share of Top 3 and Top 5 Players/Suppliers
        2.4.3 Mergers & Acquisitions, Expansion in United States Market
    2.5 United States Players/Suppliers Bioengineered Protein Drugs Manufacturing Base Distribution, Sales Area, Product Type

3 United States Bioengineered Protein Drugs Sales (Volume) and Revenue (Value) by Region (2012-2017)
    3.1 United States Bioengineered Protein Drugs Sales and Market Share by Region (2012-2017)
    3.2 United States Bioengineered Protein Drugs Revenue and Market Share by Region (2012-2017)
    3.3 United States Bioengineered Protein Drugs Price by Region (2012-2017)

4 United States Bioengineered Protein Drugs Sales (Volume) and Revenue (Value) by Type (Product Category) (2012-2017)
    4.1 United States Bioengineered Protein Drugs Sales and Market Share by Type (Product Category) (2012-2017)
    4.2 United States Bioengineered Protein Drugs Revenue and Market Share by Type (2012-2017)
    4.3 United States Bioengineered Protein Drugs Price by Type (2012-2017)
    4.4 United States Bioengineered Protein Drugs Sales Growth Rate by Type (2012-2017)

5 United States Bioengineered Protein Drugs Sales (Volume) by Application (2012-2017)
    5.1 United States Bioengineered Protein Drugs Sales and Market Share by Application (2012-2017)
    5.2 United States Bioengineered Protein Drugs Sales Growth Rate by Application (2012-2017)
    5.3 Market Drivers and Opportunities

6  United States Bioengineered Protein Drugs Players/Suppliers Profiles and Sales Data
    6.1 Abbott Laboratories
        6.1.1 Company Basic Information, Manufacturing Base and Competitors
        6.1.2 Bioengineered Protein Drugs Product Category, Application and Specification
            6.1.2.1 Product A
            6.1.2.2 Product B
        6.1.3 Abbott Laboratories Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.1.4 Main Business/Business Overview
    6.2 F. Hoffmann-La Roche Ltd
        6.2.2 Bioengineered Protein Drugs Product Category, Application and Specification
            6.2.2.1 Product A
            6.2.2.2 Product B
        6.2.3 F. Hoffmann-La Roche Ltd Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.2.4 Main Business/Business Overview
    6.3 Amgen, Inc.
        6.3.2 Bioengineered Protein Drugs Product Category, Application and Specification
            6.3.2.1 Product A
            6.3.2.2 Product B
        6.3.3 Amgen, Inc. Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.3.4 Main Business/Business Overview
    6.4 Bayer AG
        6.4.2 Bioengineered Protein Drugs Product Category, Application and Specification
            6.4.2.1 Product A
            6.4.2.2 Product B
        6.4.3 Bayer AG Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.4.4 Main Business/Business Overview
    6.5 Merck & Co., Inc.
        6.5.2 Bioengineered Protein Drugs Product Category, Application and Specification
            6.5.2.1 Product A
            6.5.2.2 Product B
        6.5.3 Merck & Co., Inc. Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.5.4 Main Business/Business Overview
    6.6 Dr. Reddy?s Laboratories Ltd.
        6.6.2 Bioengineered Protein Drugs Product Category, Application and Specification
            6.6.2.1 Product A
            6.6.2.2 Product B
        6.6.3 Dr. Reddy?s Laboratories Ltd. Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.6.4 Main Business/Business Overview
    6.7 Biocon Ltd.
        6.7.2 Bioengineered Protein Drugs Product Category, Application and Specification
            6.7.2.1 Product A
            6.7.2.2 Product B
        6.7.3 Biocon Ltd. Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.7.4 Main Business/Business Overview
    6.8 Eli Lilly and Company
        6.8.2 Bioengineered Protein Drugs Product Category, Application and Specification
            6.8.2.1 Product A
            6.8.2.2 Product B
        6.8.3 Eli Lilly and Company Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.8.4 Main Business/Business Overview
    6.9 Sanofi
        6.9.2 Bioengineered Protein Drugs Product Category, Application and Specification
            6.9.2.1 Product A
            6.9.2.2 Product B
        6.9.3 Sanofi Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.9.4 Main Business/Business Overview
    6.10 GlaxoSmithKline plc
        6.10.2 Bioengineered Protein Drugs Product Category, Application and Specification
            6.10.2.1 Product A
            6.10.2.2 Product B
        6.10.3 GlaxoSmithKline plc Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.10.4 Main Business/Business Overview
    6.11 Johnson & Johnson
    6.12 JanssenNovartis AG
    6.13 Panacea Biotec
    6.14 ProBioGen AG

7 Bioengineered Protein Drugs Manufacturing Cost Analysis
    7.1 Bioengineered Protein Drugs Key Raw Materials Analysis
        7.1.1 Key Raw Materials
        7.1.2 Price Trend of Key Raw Materials
        7.1.3 Key Suppliers of Raw Materials
        7.1.4 Market Concentration Rate of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
        7.2.1 Raw Materials
        7.2.2 Labor Cost
        7.2.3 Manufacturing Expenses
    7.3 Manufacturing Process Analysis of Bioengineered Protein Drugs

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
    8.1 Bioengineered Protein Drugs Industrial Chain Analysis
    8.2 Upstream Raw Materials Sourcing
    8.3 Raw Materials Sources of Bioengineered Protein Drugs Major Manufacturers in 2016
    8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
    9.1 Marketing Channel
        9.1.1 Direct Marketing
        9.1.2 Indirect Marketing
        9.1.3 Marketing Channel Development Trend
    9.2 Market Positioning
        9.2.1 Pricing Strategy
        9.2.2 Brand Strategy
        9.2.3 Target Client
    9.3 Distributors/Traders List

10 Market Effect Factors Analysis
    10.1 Technology Progress/Risk
        10.1.1 Substitutes Threat
        10.1.2 Technology Progress in Related Industry
    10.2 Consumer Needs/Customer Preference Change
    10.3 Economic/Political Environmental Change

11 United States Bioengineered Protein Drugs Market Size (Value and Volume) Forecast (2017-2022)
    11.1 United States Bioengineered Protein Drugs Sales Volume, Revenue Forecast (2017-2022)
    11.2 United States Bioengineered Protein Drugs Sales Volume Forecast by Type (2017-2022)
    11.3 United States Bioengineered Protein Drugs Sales Volume Forecast by Application (2017-2022)
    11.4 United States Bioengineered Protein Drugs Sales Volume Forecast by Region (2017-2022)

12 Research Findings and Conclusion

13 Appendix
    13.1 Methodology/Research Approach
        13.1.1 Research Programs/Design
        13.1.2 Market Size Estimation
        13.1.3 Market Breakdown and Data Triangulation
    13.2 Data Source
        13.2.1 Secondary Sources
        13.2.2 Primary Sources
    13.3 Disclaimer